PfSPZ (NF54) Challenge

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02773979 Comparator	Sep 2016 → Jan 2018	Plasmodium falciparum malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	PfSPZ (NF54) Challenge	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02773979 ↗
Known as	PfSPZ	“PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis.” PMID 34048504 ↗ May 2021
Known as	PfSPZ Challenge	“PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis.” PMID 34048504 ↗ May 2021
Known as	Sanaria PfSPZ Challenge	“escalating doses of Sanaria PfSPZ Challenge administered by DVI on varying schedules” NCT02773979 ↗
Modality	Vaccine	“PfSPZ Challenge vaccine” NCT02773979 ↗
Route	Intravenous	“At 10 weeks after the third administration of study vaccine or placebo, all subjects within the three groups will receive the PfSPZ Challenge by direct venous injection” NCT02773979 ↗